Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.

导出 OA

翻译打印收藏纠错

作者： Robert,Stuver ^[1] ; Steven M,Horwitz ^[1] ; Ranjana H,Advani ^[2] ; Julie M,Vose ^[3] ; Hun Ju,Lee ^[4] ; Neha,Mehta-Shah ^[5] ; Jasmine M,Zain ^[6] ; Bradley,Haverkos ^[7] ; Mary Jo,Lechowicz ^[8] ; Alison J,Moskowitz ^[1] ; Luu Q,Pham ^[9] ; Elizabeth,Leyden ^[3] ; Stephen M,Ansell ^[10] ; Matthew A,Lunning ^[3]

作者单位： Memorial Sloan Kettering Cancer Center, Manhattan, New York, USA. ^[1] Stanford University, Stanford, California, USA. ^[2] University of Nebraska Medical Center, Omaha, Nebraska, USA. ^[3] MD Anderson Cancer Center, Houston, Texas, USA. ^[4] Washington University in St. Louis, St. Louis, Missouri, USA. ^[5] City of Hope, Duarte, California, USA. ^[6] University of Colorado, Boulder, Colorado, USA. ^[7] Emory University, Atlanta, Georgia, USA. ^[8] Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA. ^[9] Mayo Clinic, Rochester, Minnesota, USA. ^[10]

关键词 T-cell lymphoma clinical trials lymphomas malignant lymphomas non-Hodgkins lymphoma trials

主题词人类(Humans);淋巴瘤, T细胞, 外周(Lymphoma, T-Cell, Peripheral);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);缓解诱导(Remission Induction)

DOI 10.1111/bjh.18885

PMID 37217196

发布时间 2024-07-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交